glp-1 agonists blindness risk GLP 1 GLP-1 Receptor Agonists and Sight-Threatening

Methods We searched for eligible trials published in PubMed (last search in February 2015) by using the following search algorithm: (Glucagon-like peptide-1 receptor agonists OR exenatide OR liraglutide OR lixisenatide OR albiglutide OR dulaglutide) AND (side effects OR adverse effects OR safety OR gastrointestinal OR pancreas OR liver OR cardiovascular OR skin OR allergy OR angioedema OR immune system OR renal OR kidney OR infection OR central nervous system OR blood OR malignancy OR cancer) The search was limited by the following criteria: - Published in the English language

The incretin effect is exclusively glucose-dependent and critical for the maintenance of glucose homeostasis

Of those, 43.5% posted about at least one side effect

Like pancreatic -cells, the intestinal L-cells secrete PGDPs simultaneously and in equimolar concentrations

European Journal of Pharmacology 2018

Heres what to know The federal government has launched a new program to make GLP-1 weight loss drugs more affordable for older Americans